Psychopharmacology

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

Learn why patients skip psych meds and how to boost adherence with stigma-free dialogue, routine hacks, family support, and deprescribing tips.

Learn more about the treatment of depression, selective serotonin reuptake inhibitors, and pregnancy in this podcast.

New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.

Bupropion may cause dose-linked tinnitus; this case shows symptoms improve after dose reduction, helping manage depression without stopping treatment.

Experts share more on research developments of remternetug for Alzheimer disease.

A pharma expert and clinician shares perspectives on developing treatments.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

Learn more about the history of pharmacogenomics.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.

A relationship between inflammatory skin disease and depression revealed in new research.

A novel form of agomelatine shows positive initial results.

Phase 2 trial of oveporexton for narcolepsy type 1 finds improvement on measures of cognition, in addition to previously demonstrated improved hallmark symptom of nighttime wakefulness.

Psychiatry experts unpack why off-label medications are common and how evidence and dosing guide care.

Further data shared on LB-102 for schizophrenia.

Tazbentetol interim results show improvement in schizophrenia symptoms.

New expert guidance shows how to safely review and taper psychiatric medications, weighing efficacy, risks, interactions, and patient input in mood disorders.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

Experts discuss why early treatment and tailored combos can curb bipolar disorder.

An expert shares why new kratom variants have dangerous implications for substance use disorder.

See why ketamine boosts outcomes for treatment‑resistant depression.

New serotonergic therapies show durable relief in Phase II anxiety trials, as clinicians and patients partner to tackle unmet depression needs.

New evidence suggests age-adjusted eGFR cutoffs refine CKD risk, guiding safer lithium use and avoiding unnecessary kidney alarms.

Discover more on the uses and context of ketamine.

New RCT shows DBT cuts suicidal crises and self-harm in borderline personality disorder more than SSRIs, though benefits fade after treatment.